会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明申请
    • Particles for Treatment of Pulmonary Infection
    • 用于治疗肺部感染的颗粒
    • US20080213373A1
    • 2008-09-04
    • US11720595
    • 2005-10-19
    • David A. EdwardsJennifer FiegelJean Sung
    • David A. EdwardsJennifer FiegelJean Sung
    • A61K9/14
    • A61K9/0075A61K9/1617A61K9/1694Y10S514/924
    • Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration. Optionally, the nanoparticles are coated, such as with a surfactant or protein coating. The formulation may be administered as a powder or administered as a solution or via an enteral or non-pulmonary parenteral route of administration. The formulation is preferably administered as a pulmonary formulation. In the preferred embodiment for treatment of TB, the vaccine is a BCG vaccine that is stable at room temperature, or is an antibiotic effective against TB, such as capreomycin or PA-824, loaded at a very high percentage into the microparticles or nanoparticles. In one embodiment, a patient is treated with formulations delivering both antibiotic and vaccine.
    • 已经开发了治疗或减少呼吸道感染传播的制剂,特别是慢性或耐药性感染,特别是结核病(TB),严重急性呼吸综合征(SARS),脑膜炎球菌性脑膜炎,呼吸道合胞病毒(RSV),流感和小痘 。 制剂包括纳米颗粒的微粒,纳米颗粒或骨料形式的药物或疫苗,以及任选的可以通过吸入递送的载体。 通过吸入器给药可以通过绕过胃和肝来避开与口服或可注射药物相关的问题,并将药物直接送入肺部。 在一个实施方案中,含有该试剂的颗粒是大的多孔气溶胶颗粒(LPPs)。 在另一个实施方案中,颗粒是纳米颗粒,其可以作为具有微米直径的多孔纳米颗粒聚集体施用,其在施用后分散到纳米颗粒中。 任选地,包覆纳米颗粒,例如用表面活性剂或蛋白质涂层。 制剂可以粉末形式施用或作为溶液给药或通过肠内或非肺部非肠道途径给药。 制剂优选作为肺制剂施用。 在用于治疗结核病的优选实施方案中,疫苗是在室温下稳定的BCG疫苗,或者是针对TB有效的抗生素,例如卷曲霉素或PA-824,其以非常高的百分比加载到微粒或纳米颗粒中。 在一个实施方案中,用递送抗生素和疫苗的制剂治疗患者。
    • 44. 发明授权
    • Amorphous porous particles for deep lung delivery
    • 用于深肺输送的无定形多孔颗粒
    • US06447752B2
    • 2002-09-10
    • US09888781
    • 2001-06-25
    • David A. EdwardsGiovanni CaponettiJeffrey S. HrkachNoah LotanJustin HanesRobert S. LangerAbdellaziz Ben-Jebria
    • David A. EdwardsGiovanni CaponettiJeffrey S. HrkachNoah LotanJustin HanesRobert S. LangerAbdellaziz Ben-Jebria
    • A61K912
    • A61K9/0075A61K9/1647A61K31/137Y10S514/826Y10S514/851
    • Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a biodegradable material and have a mass density less than 0.4 g/cm3/. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear &agr;-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, porous particles having a relatively large mean diameter, for example greater than 5 &mgr;m, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The porous particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide variety of therapeutic agents.
    • 提供用于向肺系统递送药物的改进的多孔颗粒,以及用于其合成和给药的方法。 在优选的实施方案中,多孔颗粒由可生物降解的材料制成,其质量密度小于0.4g / cm 3 /。 颗粒可以由可生物降解的材料如可生物降解的聚合物形成。 例如,颗粒可以由官能化聚酯接枝共聚物形成,该聚酯接枝共聚物由具有至少一个氨基酸基团的直链α-羟基酸聚酯主链和至少一个从氨基酸延伸的聚(氨基酸)侧链组成 集团在聚酯骨干。 在一个实施方案中,具有相对大的平均直径,例如大于5um的多孔颗粒可用于增强治疗剂递送至肺的肺泡区域。 掺入治疗剂的多孔颗粒可以有效地雾化,用于给予呼吸道以允许全身或局部递送多种治疗剂。
    • 45. 发明授权
    • Methods of reliably allocating, de-allocating, re-allocating, and reclaiming objects in a symmetrically blocked nonvolatile memory having a bifurcated storage architecture
    • 在具有分叉存储架构的对称封锁非易失性存储器中可靠地分配,分配,重新分配和回收对象的方法
    • US06311290B1
    • 2001-10-30
    • US09055032
    • 1998-04-03
    • Robert N. HasbunDavid A. EdwardsAndrew H. GafkenChristopher J. Spiegel
    • Robert N. HasbunDavid A. EdwardsAndrew H. GafkenChristopher J. Spiegel
    • H02H305
    • G06F12/0246G06F11/0793G06F2212/7205Y10S707/99953
    • Methods of reliably allocating, writing, reading, de-allocating, re-allocating, and reclaiming space within a nonvolatile memory having a bifurcated storage architecture are described. Allocation, writing, reading, de-allocating, re-allocating, and reclamation are handled by a memory manager. The memory manager tracks the progress of each process during execution in order to detect whether a selected process was interrupted for purposes of recovery. The nonvolatile memory is recovered to a known state during initialization. Initialization includes the step of determining a recovery state from a recovery state lookup table. A selected recovery process is selected in accordance with the recovery state lookup table. A restart level for the selected process is determined from a corresponding restart state lookup table. The selected process is then restarted at the restart level. In one embodiment, a method of managing a nonvolatile memory includes the step of identifying an interrupted process from at least one of an allocation, a reclamation, a configuration header reclaim, and a re-allocation process initiated on the nonvolatile memory. A recovery process is selected for the interrupted process. An entry point into the recovery process is determined. The selected recovery process is then restarted at the entry point.
    • 描述了在具有分叉存储结构的非易失性存储器内可靠地分配,写入,读取,分配,重新分配和回收空间的方法。 分配,写入,读取,取消分配,重新分配和回收由内存管理员处理。 内存管理器在执行期间跟踪每个进程的进度,以便检测所选进程是否为了恢复目的而中断。 在初始化期间,非易失性存储器恢复到已知状态。 初始化包括从恢复状态查找表确定恢复状态的步骤。 根据恢复状态查找表选择选择的恢复过程。 从相应的重新启动状态查找表确定所选进程的重新启动级别。 然后在重新启动级别重新启动所选进程。 在一个实施例中,管理非易失性存储器的方法包括从在非易失性存储器上发起的分配,回收,配置报头回收和重新分配过程中的至少一个识别中断的进程的步骤。 为中断的进程选择恢复过程。 确定恢复过程的入口点。 然后在入口点重新启动所选的恢复过程。
    • 46. 发明授权
    • Method and apparatus for executing a program stored in nonvolatile memory
    • 用于执行存储在非易失性存储器中的程序的方法和装置
    • US06243789B1
    • 2001-06-05
    • US09028159
    • 1998-02-23
    • Robert N. HasbunDavid A. Edwards
    • Robert N. HasbunDavid A. Edwards
    • G06F1208
    • G06F9/3812G06F12/0292G06F12/0638G06F2212/2022
    • A method of executing a program includes the step of initiating execution of the program stored contiguously without code fragmentation in a nonvolatile memory. Execution of the program is halted if the program attempts to modify a page of the nonvolatile memory. The page of nonvolatile memory is then copied to a modifiable memory. The page of nonvolatile memory is then remapped to the modifiable memory. Execution of the program is then resumed. A computer system for execution of a program includes a nonvolatile memory storing a program contiguously without code fragmentation. The computer system includes a processor for executing the program. A memory management unit generates an interrupt in response to a request to modify a page of the nonvolatile memory. Execution of the program is halted and the processor copies the page of nonvolatile memory to a modifiable memory in response to the interrupt. The processor resumes execution of the program after updating an address translation table of the memory management unit to refer to the modifiable memory for subsequent program access requests to the page of nonvolatile memory.
    • 执行程序的方法包括在非易失性存储器中开始执行连续存储的程序而没有代码碎片的步骤。 如果程序尝试修改非易失性存储器的页面,程序的执行将停止。 然后将非易失性存储器的页面复制到可修改的存储器。 然后将非易失性存储器的页面重新映射到可修改的存储器。 然后,程序的执行恢复。 用于执行程序的计算机系统包括非易失性存储器,其连续地存储程序而没有代码分段。 计算机系统包括用于执行程序的处理器。 存储器管理单元响应于修改非易失性存储器的页面的请求而产生中断。 停止执行程序,并且处理器将非易失性存储器的页面复制到可修改的存储器以响应中断。 在更新存储器管理单元的地址转换表之后,处理器恢复执行该程序,以引用可修改的存储器,以便随后的程序访问请求到非易失性存储器的页面。
    • 47. 发明授权
    • Aerodynamically light particles for pulmonary drug delivery
    • 用于肺部药物递送的空气动力学轻微颗粒
    • US6136295A
    • 2000-10-24
    • US211940
    • 1998-12-15
    • David A. EdwardsGiovanni CaponettiJeffrey S. HrkachNoah LotanJustin HanesAbdell Aziz Ben-JebriaRobert S. Langer
    • David A. EdwardsGiovanni CaponettiJeffrey S. HrkachNoah LotanJustin HanesAbdell Aziz Ben-JebriaRobert S. Langer
    • A61K9/12A61K9/00A61K9/14A61K9/16A61K9/72A61K31/137A61K47/32A61L9/04A61F2/00
    • A61K9/0075A61K31/137A61K9/1647
    • Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a tap density less than 0.4 g/cm.sup.3 and a mass mean diameter between 5 .mu.m and 30 .mu.m. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear .alpha.-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 .mu.m, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The aerodynamically light particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide variety of therapeutic agents.
    • 提供用于向肺系统输送药物的空气动力学轻微颗粒,以及用于其合成和给药的方法。 在优选的实施方案中,空气动力学轻微颗粒由可生物降解的材料制成,并且具有小于0.4g / cm 3的振实密度和5μm-30μm之间的质量平均直径。 颗粒可以由可生物降解的材料如可生物降解的聚合物形成。 例如,颗粒可以由官能化的聚酯接枝共聚物形成,该聚酯接枝共聚物由具有至少一个氨基酸基团的直链α-羟基酸聚酯主链和至少一个从氨基酸延伸的聚(氨基酸)侧链组成 集团在聚酯骨干。 在一个实施方案中,具有大平均直径(例如大于5μm)的空气动力学轻的颗粒可用于增强治疗剂递送至肺的肺泡区域。 掺入治疗剂的空气动力学轻微颗粒可以被有效地雾化,用于给予呼吸道以允许全身或局部递送多种治疗剂。
    • 48. 发明授权
    • Particles incorporating surfactants for pulmonary drug delivery
    • 含有肺部药物递送表面活性剂的颗粒
    • US5855913A
    • 1999-01-05
    • US784421
    • 1997-01-16
    • Justin HanesDavid A. EdwardsCarmen EvoraRobert Langer
    • Justin HanesDavid A. EdwardsCarmen EvoraRobert Langer
    • A61K9/00A61K9/12A61K9/14A61K9/16A61K31/135A61K31/137A61K38/28A61K38/38A61K47/48
    • A61K9/0075A61K31/135A61K31/137A61K38/28A61K38/38A61K9/1617A61K9/1623A61K9/1641A61K9/1647A61K9/1658
    • Aerodynamically light particles incorporating a surfactant on the surface thereof for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a tap density less than 0.4 g/cm.sup.3 and a mass mean diameter between 5 .mu.m and 30 .mu.m. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of poly(lactic acid) or poly(glycolic acid) or copolymers thereof. Alternatively, the particles may be formed solely of the drug or diagnostic agent and a surfactant. Surfactants can be incorporated on the particle surface for example by coating the particle after particle formation, or by incorporating the surfactant in the material forming the particle prior to formation of the particle. Exemplary surfactants include phosphoglycerides such as L-.alpha.-phosphatidylcholine dipalmitoyl. The aerodynamically light particles incorporating a therapeutic or diagnostic agent and a surfactant may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide a variety of therapeutic agents.
    • 提供了在其表面上并入表面活性剂用于向肺系统输送药物的空气动力学轻微颗粒,以及用于其合成和给药的方法。 在优选的实施方案中,空气动力学轻微颗粒由可生物降解的材料制成,并且具有小于0.4g / cm 3的振实密度和5μm-30μm之间的质量平均直径。 颗粒可以由可生物降解的材料如可生物降解的聚合物形成。 例如,颗粒可以由聚(乳酸)或聚(乙醇酸)或其共聚物形成。 或者,颗粒可以仅由药物或诊断剂和表面活性剂形成。 表面活性剂可以结合在颗粒表面上,例如通过在颗粒形成之后涂覆颗粒,或者通过在形成颗粒之前将表面活性剂并入形成颗粒的材料中。 示例性的表面活性剂包括磷酸甘油酯如L-α-磷脂酰胆碱二棕榈酰基。 包含治疗剂或诊断剂和表面活性剂的空气动力学轻微颗粒可以有效地雾化,用于给予呼吸道以允许全身或局部递送各种各样的治疗剂。
    • 49. 发明授权
    • Method for directing groundwater flow and treating groundwater in situ
    • US5833388A
    • 1998-11-10
    • US681701
    • 1996-07-29
    • David A. EdwardsVincent B. Dick
    • David A. EdwardsVincent B. Dick
    • B09C1/00B09C1/02B09C1/08B09C1/10B09B3/00E02D3/11
    • B09C1/08B09C1/002B09C1/02B09C1/10B09C2101/00
    • The present invention relates to a method for treating groundwater in situ in rock or soil. An elongate permeable upgradient zone and an elongate permeable downgradient zone, each in hydraulic communication with a permeable subsurface treatment zone and having a major axis parallel to a non-zero component of the general flow direction, are provided in the subsurface by any of a number of construction methods. The upgradient zone, downgradient zone, and treatment zone are situated within the subsurface medium and have permeabilities substantially greater than the adjacent subsurface medium's permeability. Groundwater is allowed to move from the subsurface medium adjacent to the upgradient zone into the upgradient zone, where the groundwater refracts and moves to a treatment zone. After being treated in the treatment zone by an in situ treatment process, such as a process employing air sparging, sorption or reaction with zero-valent iron, the groundwater moves into, through, and out of the downgradient zone into the subsurface medium adjacent to the downgradient zone. The method does not require pumping. A method for directing groundwater around a particular location to prevent contamination of the groundwater by a contaminant located at the particular location, to prevent migration of a contaminant located at the particular location, to reduce the flow velocity of groundwater in the particular location, or to increase the residence time in an in situ treatment center located downgradient from the particular location is also disclosed.
    • 50. 发明授权
    • Bottle holder accessory for an inline rollerskate
    • 用于在线滚子的瓶架附件
    • US5344055A
    • 1994-09-06
    • US105642
    • 1993-08-12
    • David A. Edwards
    • David A. Edwards
    • A43B5/16A63C11/00A63C17/00B60R7/00
    • A63C17/26A43B5/16A63C17/0006A63C17/06Y10S224/926
    • A bottle holder accessory for an inline rollerskate includes a holder structure adapted to hold a water bottle and a support structure adapted to mount the holder structure to the inline rollerskate. The bottle holder structure has a lower portion adapted to receive the water bottle therein and an upper portion adapted to releasably secure the water bottle on the lower portion. The support structure has a bracket adapted to support the bottle holder structure in a cantilevered position rearwardly of the bracket and a pair of laterally-spaced attachment arms connected to the lower end of the bracket and extending generally forwardly therefrom. The attachment arms are adapted to extend along and be fastened to opposite sides of a mobile undercarriage of the inline rollerskate. Elongated slots are defined in the attachment arms to receive at least some of the opposite ends of the axles which rotatably mount the wheels of the undercarriage. Also, fasteners are used to secure the opposite ends of the axles extending outwardly through the slots to the attachment arms and thereby mount the bottle holder accessory to opposite ends of the axles.
    • 用于在线滚轮的瓶保持器附件包括适于保持水瓶的保持器结构和适于将保持器结构安装到在线滚子上的支撑结构。 瓶架结构具有适于在其中容纳水瓶的下部,以及适于将水瓶可释放地固定在下部上的上部。 支撑结构具有支架,其适于将瓶保持器结构支撑在支架后方的悬臂位置中,以及一对横向间隔的连接臂,其连接到支架的下端并从其大致向前延伸。 连接臂适于沿直线滚轮的移动底盘的相对侧延伸并且被紧固。 细长的狭槽被限定在连接臂中,以容纳可旋转地安装起落架的车轮的轴的至少一些相对的端部。 此外,紧固件用于固定轴的相对端部,其通过狭槽向外延伸到连接臂,从而将瓶保持器附件安装到轴的相对端。